Nisa Investment Advisors LLC Holds Position in NxStage Medical, Inc. (NASDAQ:NXTM)
Nisa Investment Advisors LLC held its stake in shares of NxStage Medical, Inc. (NASDAQ:NXTM) during the second quarter, Holdings Channel reports. The fund owned 16,180 shares of the medical device company’s stock at the end of the second quarter. Nisa Investment Advisors LLC’s holdings in NxStage Medical were worth $352,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in shares of NxStage Medical during the first quarter worth $140,000. Ameritas Investment Partners Inc. acquired a new stake in shares of NxStage Medical during the first quarter worth $148,000. Menta Capital LLC acquired a new stake in shares of NxStage Medical during the first quarter worth $212,000. Jane Street Group LLC acquired a new stake in shares of NxStage Medical during the first quarter worth $213,000. Finally, PEAK6 Investments L.P. purchased a new stake in NxStage Medical during the first quarter worth approximately $214,000. Hedge funds and other institutional investors own 91.11% of the company’s stock.
NxStage Medical, Inc. (NXTM) traded down 0.20% during midday trading on Friday, reaching $29.22. 1,627,197 shares of the company were exchanged. The firm’s market capitalization is $1.93 billion. NxStage Medical, Inc. has a 52 week low of $20.45 and a 52 week high of $30.80. The company has a 50-day moving average of $24.92 and a 200 day moving average of $25.85.
NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings data on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). The company had revenue of $92.20 million during the quarter, compared to analyst estimates of $96.47 million. NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. NxStage Medical’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.03) earnings per share. Equities analysts predict that NxStage Medical, Inc. will post ($0.04) earnings per share for the current year.
A number of equities research analysts recently commented on the stock. Jefferies Group LLC lowered shares of NxStage Medical from a “buy” rating to a “hold” rating and lowered their price target for the company from $33.00 to $30.00 in a report on Tuesday. BTIG Research lowered shares of NxStage Medical from a “buy” rating to a “neutral” rating in a report on Friday. Northland Securities reiterated a “hold” rating and set a $30.00 price target on shares of NxStage Medical in a report on Monday, August 7th. William Blair lowered shares of NxStage Medical from an “outperform” rating to a “market perform” rating in a report on Monday, August 7th. Finally, Zacks Investment Research upgraded shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a report on Thursday. One research analyst has rated the stock with a sell rating and eight have given a hold rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $30.29.
In other news, SVP Matthew W. Towse sold 4,300 shares of NxStage Medical stock in a transaction on Monday, May 22nd. The stock was sold at an average price of $21.36, for a total transaction of $91,848.00. Following the completion of the sale, the senior vice president now directly owns 29,637 shares in the company, valued at $633,046.32. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Winifred L. Swan sold 3,500 shares of NxStage Medical stock in a transaction on Monday, May 15th. The stock was sold at an average price of $21.94, for a total value of $76,790.00. Following the sale, the senior vice president now owns 17,770 shares of the company’s stock, valued at $389,873.80. The disclosure for this sale can be found here. Insiders have sold 53,900 shares of company stock valued at $1,404,073 over the last ninety days. 4.70% of the stock is owned by insiders.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.